SOX22 Antibody (PCRP-SOX12-1E4)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-23900
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # PCRP-SOX12-1E4
Concentration
0.2 mg/ml
Product Specifications
Immunogen
Recombinant fragment (around aa31-110) of human SOX22 protein
Localization
Nucleus.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Description
Store at 2 to 8C. Non-hazardous. No MSDS required.
Scientific Data Images for SOX22 Antibody (PCRP-SOX12-1E4)
Protein Array: SOX22 Antibody (PCRP-SOX12-1E4) [NBP3-23900] -
Analysis of Protein Array containing more than 19,000 full-length human proteins using SOX22 antibody (PCRP-SOX12-1E4)Flow Cytometry: SOX22 Antibody (PCRP-SOX12-1E4) [NBP3-23900] -
Flow cytometric analysis of PFA-fixed HeLa cells.SOX22 antibody (PCRP-SOX12-1E4) followed by goat anti-mouse IgG-CF488 (blue), unstained cells (red).Applications for SOX22 Antibody (PCRP-SOX12-1E4)
Application
Recommended Usage
Flow Cytometry
1-2ug/million cells
Application Notes
Optimal dilution for a specific application should be determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10mM PBS with 0.05% BSA
Preservative
0.05% Sodium Azide
Concentration
0.2 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: SOX22
Alternate Names
Protein SOX-22, SOX-22 protein, SOX22transcription factor SOX-12, SRY (sex determining region Y)-box 12, SRY (sex determining region Y)-box 22, SRY-related HMG-box gene 22
Gene Symbol
SOX12
Additional SOX22 Products
Product Documents for SOX22 Antibody (PCRP-SOX12-1E4)
Product Specific Notices for SOX22 Antibody (PCRP-SOX12-1E4)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...